Syncom Formulations (India) Profile
Key Indicators
- Authorised Capital ₹ 95.00 Cr
- Paid Up Capital ₹ 94.00 Cr
- Company Age 36 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 100.00 Cr
- Satisfied Charges ₹ 56.68 Cr
- Revenue Growth -8.05%
- Profit Growth -32.16%
- Ebitda -45.83%
- Net Worth 18.47%
- Total Assets 5.69%
About Syncom Formulations (India)
Syncom Formulations (India) Limited (SFIL) is a leading Public Limited Indian Non-Government Company incorporated in India on 21 June 1988 and has a history of 36 years and seven months. Its registered office is in Mumbai, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524470.
The Corporate was formerly known as Syncom Formulations (India) Pvt Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 95.00 Cr and a paid-up capital of Rs 94.00 Cr.
The company currently has active open charges totaling ₹100.00 Cr. The company has closed loans amounting to ₹56.68 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Syncom Formulations (India) Limited India are Vaishali Agrawal as COMPANY SECRETARY and Ankit Bankda as Cfo. Vijay Bankda, Kedarmal Bankda, Ankit Jain, and Three other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
L24239MH1988PLC047759
- Company No.
047759
- Stock Symbol
BSE : 524470
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Jun 1988
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Mumbai
Industry
What products or services does Syncom Formulations (India) Limited offer?
Syncom Formulations (India) Limited offers a wide range of products and services, including Packaging Films & Foils, Plastic Film, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Pharmaceutical Syrup, Oral Suspension, Multivitamin Syrup & Drops, Common Disease Medicines, Eye Drops, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Syncom Formulations (India)?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Bankda  | Managing Director | 01-Dec-1999 | Current |
| Vaishali Agrawal | Company Secretary | 31-May-2023 | Current |
| Ankit Bankda | CFO | 01-Apr-2014 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kedarmal Bankda | Whole-Time Director | 13-Apr-1992 | Current |
| Ankit Jain | Director | 14-Aug-2023 | Current |
| Rinki Bankda | Whole-Time Director | 13-Aug-2014 | Current |
| Ritesh Lunkad | Director | 14-Aug-2023 | Current |
| Ruchi Jindal | Director | 28-Jun-2022 | Current |
Financial Performance of Syncom Formulations (India).
Syncom Formulations (India) Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.05% decrease. The company also saw a substantial fall in profitability, with a 32.16% decrease in profit. The company's net worth Soared by an impressive increase of 18.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Syncom Formulations (India)?
In 2022, Syncom Formulations (India) had a promoter holding of 46.12% and a public holding of 53.87%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sante Biotech Private LimitedVijay Bankda and Kedarmal Bankda are mutual person
- Synmex Pharma Private Limited
Vijay Bankda and Kedarmal Bankda are mutual person
- Vincit Biotech International Private Limited
Vijay Bankda and Kedarmal Bankda are mutual person
Charges (Loans)
₹100.00 Cr
₹56.68 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 100.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Dec 2020 | Hdfc Bank Limited | ₹100.00 Cr | Open |
| 23 May 2002 | Dena Bank | ₹12.77 Cr | Satisfied |
| 23 May 2002 | Dena Bank | ₹12.77 Cr | Satisfied |
| 27 Mar 2000 | Dena Bank | ₹4.00 Cr | Satisfied |
| 15 Mar 2000 | Dena Bank | ₹6.70 Cr | Satisfied |
How Many Employees Work at Syncom Formulations (India)?
Syncom Formulations (India) has a workforce of 814 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Syncom Formulations (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Syncom Formulations (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
